Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study

SG showed modest activity after EV in heavily pretreated patients with aUC. ORR with SG after EV was lower than reported in phase 2 and phase 3 clinical trials for SG in the postplatinum/ICI setting.

Authors

Institutions

Publication Details

Journal
Urologic Oncology Seminars and Original Investigations
Published
2025-10-28
DOI
https://doi.org/10.1016/j.urolonc.2025.09.025
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study

Omar Alhalabi, Matthew T. Campbell, Irene Tsung, Cindy Jiang et al.
Urologic Oncology Seminars and Original Investigations
Bladder and Urothelial Cancer Treatments
article

Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study

Omar Alhalabi, Matthew T. Campbell, Irene Tsung, Cindy Jiang, Ali Raza Khaki, Arnab Basu, Albert Jang, Hamid Emamekhoo, Petros D. Grivas, Vadim S. Koshkin, Rafee Talukder, Ajjai Alva, Dory Freeman, Tanya Jindal, Deepak Kilari, Jason Robert Brown, I. Epstein, Charles B. Nguyen, Matthew P. Davidsohn, Amanda Nizam, Amy K. Taylor, Joaquim Bellmunt, Abhishek Tripathi, Sumit Shah, Dimitra Rafailia Bakaloudi, Cameron Pywell, Nancy B. Davis, Salvador Jaime‐Casas, Sean T. Evans, Eugene Oh, Michael Glover, Dongjun Shin, Shilpa Gupta, Mehmet Asim Bilen, Emily Lemke
article en

Abstract

SG showed modest activity after EV in heavily pretreated patients with aUC. ORR with SG after EV was lower than reported in phase 2 and phase 3 clinical trials for SG in the postplatinum/ICI setting.

Urologic Oncology Seminars and Original InvestigationsVol. 44(1)
Froedtert Hospital (US), Cleveland Clinic (US), The University of Texas MD Anderson Cancer Center (US), Emory University (US), University of California, San Francisco (US), Vanderbilt University (US), University of Washington (US), University of Michigan (US), University of Alabama at Birmingham (US), Fred Hutch Cancer Center (US), University of Wisconsin Carbone Cancer Center (US), City of Hope (US), Dana-Farber Cancer Institute (US), Michigan Center for Translational Pathology (US), University Hospitals Seidman Cancer Center (US), UCSF Helen Diller Family Comprehensive Cancer Center (US), Vanderbilt-Ingram Cancer Center, O'Neal Comprehensive Cancer Center, Stanford University (US)
Openalex Percentile: Top 51%
Bladder and Urothelial Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.